Moleculin Biotech, Inc. (0K2H.L)

4,4300 +0,0800 (+1,84%) Alla chiusura: 02:32PM BST

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
(713) 300-5160
https://moleculin.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 18

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Walter V. Klemp	Founder, Chairman, President & CEO	894,54k	N/D	1960
Mr. Jonathan P. Foster CPA	Executive VP & CFO	611,17k	N/D	1964
Dr. Donald H. Picker Ph.D.	Chief Scientific Officer	486,44k	N/D	1946
Dr. Waldemar Priebe Ph.D.	Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board	N/D	N/D	N/D
Dr. Robert C. Shepard FACP, M.D.	Chief Medical Officer of Annamycin	N/D	N/D	1952
Dr. John Paul Waymack M.D., Sc.D.	Senior Chief Medical Officer	N/D	N/D	1952
Dr. Sandra L. Silberman M.D., Ph.D.	Chief Medical Officer of New Products	N/D	N/D	1956
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.	European Chief Medical Officer	N/D	N/D	N/D
Ms. Jacqueline Northcut	Consultant	51,11k	N/D	1962
Mr. Louis Ploth Jr.	Independent Advisor	118,49k	N/D	1954

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Governance aziendale

L'ISS Governance QualityScore di Moleculin Biotech, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.